An analysis on validity of distribution of biomarkers, exploration of correlation between biomarker outliers and adverse events under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 2 study)

Trial Profile

An analysis on validity of distribution of biomarkers, exploration of correlation between biomarker outliers and adverse events under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 2 study)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation; Paroxysmal atrial fibrillation
  • Focus Biomarker; Pharmacodynamics
  • Acronyms R-mark (CVI ARO 2) study
  • Most Recent Events

    • 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 01 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top